(1) PAREXEL International Corp. (NASDAQ:PRXL) triggered: 12/17/2014
PAREXEL International is a biopharmaceutical services company providing clinical research, clinical logistics, medical communications, consulting, commercialization and technology products and services to the pharmaceutical, biotechnology, and medical device industries. Co.'s product and service offerings include, but not limited to: clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics/outcomes research, medical communications, and other product development tools and services. Co. has three segments: Clinical Research Services, PAREXEL Consulting Services, and PAREXEL Informatics.
PRXL — last trade: $55.56 — Recent Insider Buys:
Tracy Ken Tsuetaki
SVP, PCMS and PACE
PRXL — Key Stats (updated Friday, December 19, 10:22 AM)
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.